More annual reports from Emergent BioSolutions Inc.:
2025 ReportPeers and competitors of Emergent BioSolutions Inc.:
Forte Biosciences, Inc.2024 ANNUAL REPORT
PREPAREDNESS TODAY, SAFER TOMORROW.
Dear fellow shareholders,
When I joined Emergent in February 2024, we embarked on a multi-year plan to stabilize, turnaround,
and ultimately transform our business. I am proud to say our stabilization phase was completed
this past fall, ahead of schedule, thanks to the dedication and commitment of our entire team.
Our strategic stabilization plan included strengthening the balance sheet and substantially
reducing debt to allow for focused, profitable growth around business lines built to compete
in today’s competitive landscape. Additionally, we implemented a leaner, more flexible
organization by streamlining our manufacturing network, including several asset divestitures.
With these actions behind us, I believe Emergent has a strong foundation, momentum,
and freedom to operate through our turnaround, the next phase of our multi-year plan.
In 2024, several important product milestones were successfully achieved, including:
• FDA approval of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) for the prevention
of mpox disease in individuals determined to be at high risk for mpox infection as the public
health outbreak hits Africa and other regions.
• Secured a number of U.S. government contracts for our medical countermeasures business,
reinforcing the longstanding partnership between Emergent and the U.S. government to meet
the country’s preparedness needs.
• Distributed 11 million cartons (includes 2 doses) of NARCAN® Nasal Spray 4 mg to customers
and patients across the U.S. and Canada.
• Roughly one year after NARCAN® Nasal Spray became the first FDA-approved over-the-counter
naloxone nasal spray, the CDC reported the first annual decrease of opioid overdose deaths
since 2018.1
• Opened a new West Coast distribution center as part of our best-in-class NARCANDirect™
distribution network, deepening our value proposition for public interest customers.
• Implemented actions to further broaden over-the-counter access of NARCAN® Nasal Spray
through retailers, public places, businesses, and workplaces.
Our products play a direct role in helping communities prepare for today’s health challenges and
tomorrow’s threats. Emergent’s 2024 results and outlook for 2025 demonstrate our ability to adapt
and evolve our business, take on new challenges, and innovate to address future urgent health
crises. We remain optimistic in our future and aspire to be the leader in solving public health
threats for communities around the world as we carry out our mission to protect and save lives.
We look forward to a strong 2025 and beyond.
JOE PAPA
President and CEO
1 Centers for Disease Control and Prevention. U.S. Overdose Deaths Decrease in 2023, First Time Since 2018. May 15, 2024.
https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2024/20240515.htm. Accessed September 26, 2024.
WE’RE
PREPARING FOR
TOMORROW BY
TRANSFORMING
OUR COMPANY
TODAY
*# )())(
(*' ) (#- # $"" (( $#
,( # )$#
$'"
##*!'%$')%*'(*#))$() $# $' 5$) (*' ) (- # )$
@CE967:D42=J62C6?565646>36C
GJ
)'#( ) $#'%$')%*'(*#))$() $# $' 5$) (*' ) (- # )$
"GJL@=LJ9FKALAGFH=JAG<>JGELG
GEEAKKAGF>AD=FME:=J
"' #) $($!*) $#( #
G02C"0<4>5%468BCA0=C0B&?42858438= CB70AC4A
6=2H2C6
&C0C4>A#C74A DA8B382C8>=>5
=2>A?>A0C8>=>A#A60=8I0C8>=
% & H4A
34=C85820C8>=">
%C@76DD:@?2=C:G6
< KM:B=;LK=N9DM9LAF?K9>=LQ AEEMFG?=FA;ALQ9F<DGL;GFKAKL=F;Q0@=
KLM
AD=< OAL@ L@= " 9 HJ=
!1 KM:EAKKAGF H9;C9?= J=D9L=< LG
5"!* 1/V"GDDGOAF?L@AKKM:EAKKAGF . :=?9FHJG;MJAF? 5"!* 1/V =P=J;AKAF?ALK>AJKLL@J==;GFLJ9;LGHLAGFKAF&MDQ
&MDQ9F</=HL=E:=J J=KH=;LAN=DQ >GDDGO=<:QL@==P=;MLAGFG>LOG;GFLJ9;LEGA;9LAGFKAF%F LOG
9<
MKAGFGN=JEAFML=K >GJL@=LJ=9LE=FLG>69AJ==:GD9NAJMKAF9
GJL@=
LJ=9LE=FLG>KE9DDHGP
JA;90@= GEH9FQ@9KLOG
H9L=FL >9EADA=K J=D9LAF? LG L@= 0!) !4 V HJG
CFGOFGJKMKH=;L=<GHAGA<GN=J
9;LMJ=<AF
3!2!!
2(,3!2!!2(,N9;;AF=AK9J=;GE:AF9FL2(,N9;;AF=0@=<=N=DGHE=FLHJG?J9EAKAFH9JLF=JK@AHOAL@*% %
29;;AF= .=K=9J;@ =FL=J 2. O@G @9K 9DJ=9
L@= LJAN9D=FL N9;;AF= AF 9<